ReNerve

ReNerve R&D per Employee

R&D Spending per Employee of ReNerve (RNV.AX) as of Oct 17, 2026.

R&D per Employee

-AUD

Last updated:

R&D Spending per Employee of ReNerve is 2026 - AUD. R&D Spending per Employee of ReNerve was 2025 - AUD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReNerve Stock analysis

What does ReNerve do? ReNerve Ltd is an Australian company operating in the Health Care sector. It develops medical devices for peripheral nerve repair and replacement, focusing on tissue-based products that accelerate regeneration and prevent scarring. The company's products include NervAlign Nerve Cuff, designed to protect repaired nerves during surgery, and NervAlign Nerve Graft, which allows nerve repair without harvesting the sural nerve. NervAlign Bionic Nerve is under development, combining polymer technology to stimulate nerve injury sites. The company's IPO occurred on November 26, 2024. Its website is https://renerve.com.au/ ReNerve is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReNerve stock

On Eulerpool you can find the complete historical development of R&D Spending per Employee ReNerve since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's ReNerve historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — ReNerve

All Key Metrics — ReNerve